Microparticles in Health and Disease

 

 Buy Article Permissions and Reprints

ABSTRACT

Microparticles (MPs) are small fragments of membrane-bound cytoplasm that are shed from the surface of an activated or apoptotic cell. Recently, their function as vectors of transcellular exchange of biologic information, in addition to better described forms of intercellular communication such as growth factors, cytokines, and chemokines, has become well recognized. Circulating levels of MPs are thought to reflect a balance between cell stimulation, proliferation, and death. The production of MPs is thought to predominately occur by vesiculation or blebbing of the cell membrane. The mechanisms governing the remodeling of the plasma membrane are complex, involving cytoskeletal changes and a shift from normal phospholipid asymmetry. Increased intracellular calcium subsequent to cell activation leads to intracellular increases in several proteins including gelsolin and calpain, as well as the activity of enzymes such as translocase, floppase, and scramblase, which play important roles in the homeostasis of the cell membrane. The membrane vesiculation and phospholipids asymmetry leading to the production of MPs occurs by the complex interplay of the proteins involved. There are several clinical conditions associated with elevated MPs, and most are also associated with an increased risk of thrombosis. Apart from cardiovascular disease and venous thromboembolism, MPs are also elevated in solid tumors with metastatic disease. The measurement of MPs is being regarded as a potential biomarker, given the range of conditions in which they are elevated and the association with prothrombotic states. The utility of measuring MPs as a diagnostic and prognostic marker is currently a subject of intense investigation. The further development of the various methods for the detection and measurement of MPs and prospective clinical trials establishing the utility of such tests will be critical prior to the routine measurement of MPs in the diagnostic laboratory.

REFERENCES

• 1 Papadimitriou J C, Drachenberg C B, Brenner D S, Newkirk C, Trump B F, Silverberg S G. “Thanatosomes”: a unifying morphogenetic concept for tumor hyaline globules related to apoptosis.  Hum Pathol. 2000;  31 1455-1465
  CrossrefPubMedGoogle Scholar
• 2 Dikov D I, Auriault M L, Boivin J F, Sarafian V S, Papadimitriou J C. Hyaline globules (thanatosomes) in gastrointestinal epithelium: pathophysiologic correlations.  Am J Clin Pathol. 2007;  127 792-799
  CrossrefPubMedGoogle Scholar
• 3 Dikov D, Roland J, Chatelet F P, Cywiner-Golenzer C, Dimitrakov J. Hyaline globules (thanatosomes) in prostate disease.  Am J Surg Pathol. 2003;  27 700-702
  CrossrefPubMedGoogle Scholar
• 4 Beranek J T. Thanatosomes and cardiomyocyte apoptotic bodies.  Hum Pathol. 2001;  32 894-895
  CrossrefPubMedGoogle Scholar
• 5 Ahn Y S. Cell-derived microparticles: 'miniature envoys with many faces'.  J Thromb Haemost. 2005;  3 884-887
  CrossrefPubMedGoogle Scholar
• 6 Greenwalt T J. The how and why of exocytic vesicles.  Transfusion. 2006;  46 143-152
  CrossrefPubMedGoogle Scholar
• 7 Freyssinet J M. Cellular microparticles: what are they bad or good for?.  J Thromb Haemost. 2003;  1 1655-1662
  CrossrefPubMedGoogle Scholar
• 8 Diaz C, Schroit A J. Role of translocases in the generation of phosphatidylserine asymmetry.  J Membr Biol. 1996;  151 1-9
  CrossrefPubMedGoogle Scholar
• 9 Morel O, Morel N, Hugel B et al.. The significance of circulating microparticles in physiology, inflammatory and thrombotic diseases.  Rev Med Interne. 2005;  26 791-801
  CrossrefPubMedGoogle Scholar
• 10 Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie B C, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation.  Blood. 2004;  104 3190-3197
  CrossrefPubMedGoogle Scholar
• 11 Horstman L L, Jy W, Jimenez J J, Bidot C, Ahn Y S. New horizons in the analysis of circulating cell-derived microparticles.  Keio J Med. 2004;  53 210-230
  CrossrefPubMedGoogle Scholar
• 12 Jacoby R C, Owings J T, Holmes J, Battistella F D, Gosselin R C, Paglieroni T G. Platelet activation and function after trauma.  J Trauma. 2001;  51 639-647
  CrossrefPubMedGoogle Scholar
• 13 Morel N, Morel O, Delabranche X et al.. Microparticles during sepsis and trauma. A link between inflammation and thrombotic processes.  Ann Fr Anesth Reanim. 2006;  25 955-966
  PubMedGoogle Scholar
• 14 Ardoin S P, Shanahan J C, Pisetsky D S. The role of microparticles in inflammation and thrombosis.  Scand J Immunol. 2007;  66 159-165
  CrossrefPubMedGoogle Scholar
• 15 Schouten M, Wiersinga W J, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis.  J Leukoc Biol. 2008;  83 536-545
  CrossrefPubMedGoogle Scholar
• 16 Chirinos J A, Heresi G A, Velasquez H et al.. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism.  J Am Coll Cardiol. 2005;  45 1467-1471
  CrossrefPubMedGoogle Scholar
• 17 Barry O P, Pratico D, Savani R C, FitzGerald G A. Modulation of monocyte-endothelial cell interactions by platelet microparticles.  J Clin Invest. 1998;  102 136-144
  CrossrefPubMedGoogle Scholar
• 18 Rectenwald J E, Myers Jr D D, Hawley A E et al.. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study.  Thromb Haemost. 2005;  94 1312-1317
  PubMedGoogle Scholar
• 19 Chirinos J A, Castrellon A, Zambrano J P et al.. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation.  Heart Rhythm. 2005;  2 525-529
  CrossrefPubMedGoogle Scholar
• 20 Andres E, Goichot B. Metabolic syndrome and venous thrombosis: potential role of microparticles.  Haematologica. 2007;  92 e64 , author reply e65
  CrossrefPubMedGoogle Scholar
• 21 Myers D D, Hawley A E, Farris D M et al.. P-selectin and leukocyte microparticles are associated with venous thrombogenesis.  J Vasc Surg. 2003;  38 1075-1089
  CrossrefPubMedGoogle Scholar
• 22 Pattanapanyasat K, Noulsri E, Fucharoen S et al.. Flow cytometric quantitation of red blood cell vesicles in thalassemia.  Cytometry B Clin Cytom. 2004;  57 23-31
  PubMedGoogle Scholar
• 23 Simak J, Holada K, Risitano A M, Zivny J H, Young N S, Vostal J G. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria.  Br J Haematol. 2004;  125 804-813
  CrossrefPubMedGoogle Scholar
• 24 Tomer A, Harker L A, Kasey S, Eckman J R. Thrombogenesis in sickle cell disease.  J Lab Clin Med. 2001;  137 398-407
  CrossrefPubMedGoogle Scholar
• 25 Cihan A Y, Pabinger I. Metabolic syndrome and venous thrombosis: potential role of microparticles.  Haematologica. 2007;  92 e065
  CrossrefPubMedGoogle Scholar
• 26 Preston R A, Jy W, Jimenez J J et al.. Effects of severe hypertension on endothelial and platelet microparticles.  Hypertension. 2003;  41 211-217
  CrossrefPubMedGoogle Scholar
• 27 Meerarani P, Moreno P R, Cimmino G, Badimon J J. Atherothrombosis: role of tissue factor; link between diabetes, obesity and inflammation.  Indian J Exp Biol. 2007;  45 103-110
  PubMedGoogle Scholar
• 28 Horstman L L, Jy W, Jimenez J J, Ahn Y S. Endothelial microparticles as markers of endothelial dysfunction.  Front Biosci. 2004;  9 1118-1135
  CrossrefPubMedGoogle Scholar
• 29 Li M, Goto S, Sakai H et al.. Enhanced shear-induced von Willebrand factor binding to platelets in acute myocardial infarction.  Thromb Res. 2000;  100 251-261
  CrossrefPubMedGoogle Scholar
• 30 Miyamoto S, Marcinkiewicz C, Edmunds Jr L H, Niewiarowski S. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GPIIb/IIIa.  Thromb Haemost. 1998;  80 225-230
  PubMedGoogle Scholar
• 31 Brisset A C, Terrisse A D, Dupouy D et al.. Shedding of active tissue factor by aortic smooth muscle cells (SMCs) undergoing apoptosis.  Thromb Haemost. 2003;  90 511-518
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Singh N, Gemmell C H, Daly P A, Yeo E L. Elevated platelet-derived microparticle levels during unstable angina.  Can J Cardiol. 1995;  11 1015-1021
  PubMedGoogle Scholar
• 33 Mallat Z, Benamer H, Hugel B et al.. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.  Circulation. 2000;  101 841-843
  CrossrefPubMedGoogle Scholar
• 34 Morel O, Jesel L, Freyssinet J M, Toti F. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis.  Thromb J. 2005;  3 15
  CrossrefPubMedGoogle Scholar
• 35 Morel O, Toti F, Bakouboula B, Grunebaum L, Freyssinet J M. Procoagulant microparticles: ‘criminal partners’ in atherothrombosis and deleterious cellular exchanges.  Pathophysiol Haemost Thromb. 2006;  35 15-22
  CrossrefPubMedGoogle Scholar
• 36 Geiser T, Sturzenegger M, Genewein U, Haeberli A, Beer J H. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves.  Stroke. 1998;  29 1770-1777
  CrossrefPubMedGoogle Scholar
• 37 Exner T, Joseph J E, Connor D, Low J, Ma D D. Increased procoagulant phospholipid activity in blood from patients with suspected acute coronary syndromes: a pilot study.  Blood Coagul Fibrinolysis. 2005;  16 375-379
  PubMedGoogle Scholar
• 38 Namba M, Tanaka A, Shimada K et al.. Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood.  Arterioscler Thromb Vasc Biol. 2007;  27 255-256
  CrossrefPubMedGoogle Scholar
• 39 Tan K T, Tayebjee M H, Lynd C, Blann A D, Lip G Y. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers.  Ann Med. 2005;  37 61-66
  CrossrefPubMedGoogle Scholar
• 40 Weber C A, Matzdorff A C, Gerriets T, Villmow T, Stolz E. Circulating microemboli in patients with myeloproliferative disorders.  Eur J Neurol. 2007;  14 199-205
  CrossrefPubMedGoogle Scholar
• 41 Villmow T, Kemkes-Matthes B, Matzdorff A C. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.  Thromb Res. 2002;  108 139-145
  CrossrefPubMedGoogle Scholar
• 42 Kelton J G, Warkentin T E, Hayward C P, Murphy W G, Moore J C. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles.  Blood. 1992;  80 2246-2251
  PubMedGoogle Scholar
• 43 Nomura S, Ishii K, Kanazawa S et al.. Significance of elevation in cell-derived microparticles after allogeneic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP.  Bone Marrow Transplant. 2005;  36 921-922
  CrossrefPubMedGoogle Scholar
• 44 Warkentin T E, Hayward C P, Boshkov L K et al.. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood. 1994;  84 3691-3699
  CrossrefPubMedGoogle Scholar
• 45 Warkentin T E. Heparin-induced thrombocytopenia: a ten-year retrospective.  Annu Rev Med. 1999;  50 129-147
  CrossrefPubMedGoogle Scholar
• 46 Brenner B. Haemostatic changes in pregnancy.  Thromb Res. 2004;  114 409-414
  CrossrefPubMedGoogle Scholar
• 47 Gonzalez-Quintero V H, Jimenez J J, Jy W et al.. Elevated plasma endothelial microparticles in preeclampsia.  Am J Obstet Gynecol. 2003;  189 589-593
  CrossrefPubMedGoogle Scholar
• 48 Laude I, Rongieres-Bertrand C, Boyer-Neumann C et al.. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight.  Thromb Haemost. 2001;  85 18-21
  PubMedGoogle Scholar
• 49 Uszynski M. Problems of recurrent loss of pregnancy: are procoagulant microparticles a risk factor for pregnancy outcome?.  Ginekol Pol. 2004;  75 642-648
  PubMedGoogle Scholar
• 50 Carp H, Dardik R, Lubetsky A et al.. Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case-controlled study.  Hum Reprod. 2004;  19 191-195
  CrossrefPubMedGoogle Scholar
• 51 Greer I A. Endothelial cell microparticles and antiphospholipid syndrome: pathologic explanations and diagnostic opportunities.  Thromb Haemost. 2004;  91 636-638
  PubMedGoogle Scholar
• 52 Dignat-George F, Camoin-Jau L, Sabatier F et al.. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome.  Thromb Haemost. 2004;  91 667-673
  Article in Thieme ConnectPubMedGoogle Scholar
• 53 Bidot C J, Jy W, Horstman L L et al.. Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia.  Hematology.. 2005;  10 451-456
  CrossrefPubMedGoogle Scholar
• 54 Pereira J, Alfaro G, Goycoolea M et al.. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.  Thromb Haemost. 2006;  95 94-99
  PubMedGoogle Scholar
• 55 Combes V, Simon A C, Grau G E et al.. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.  J Clin Invest. 1999;  104 93-102
  CrossrefPubMedGoogle Scholar
• 56 George J N, Pickett E B, Heinz R. Platelet membrane glycoprotein changes during the preparation and storage of platelet concentrates.  Transfusion. 1988;  28 123-126
  CrossrefPubMedGoogle Scholar
• 57 Scharf R E, Hanfland P. Platelet storage lesions: analysis of platelet membrane glycoproteins and platelet-derived microparticles by fluorescence-activated flow cytometry.  Transfus Sci. 1993;  14 189-194
  CrossrefPubMedGoogle Scholar
• 58 Simak J, Gelderman M P. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers.  Transfus Med Rev. 2006;  20 1-26
  CrossrefPubMedGoogle Scholar
• 59 Sierko E, Wojtukiewicz M Z. Platelets and angiogenesis in malignancy.  Semin Thromb Hemost. 2004;  30 95-108
  Article in Thieme ConnectPubMedGoogle Scholar
• 60 Bruland O S, Hoifodt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients.  Clin Cancer Res. 2005;  11 4666-4673
  CrossrefPubMedGoogle Scholar
• 61 Kim H K, Song K S, Chung J H, Lee K R, Lee S N. Platelet microparticles induce angiogenesis in vitro.  Br J Haematol. 2004;  124 376-384
  CrossrefPubMedGoogle Scholar
• 62 Mostefai H A, Andriantsitohaina R, Martinez M C. Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer.  Physiol Res. 2008;  57 311-320
  PubMedGoogle Scholar
• 63 Yang C, Mwaikambo B R, Zhu T et al.. Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways.  Am J Physiol Regul Integr Comp Physiol. 2008;  294 R467-R476
  PubMedGoogle Scholar
• 64 Kim H K, Song K S, Park Y S, Kim C M, Lee K R. Method comparison of flow cytometric assay of platelet microparticles and changes of platelet microparticles during cancer chemotherapy.  Thromb Haemost. 2002;  87 547-548
  PubMedGoogle Scholar
• 65 Pihusch R, Hohnberg B, Salat C, Pihusch M, Hiller E, Kolb H J. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic stem cell transplantation.  Ann Hematol. 2002;  81 454-461
  CrossrefPubMedGoogle Scholar
• 66 Tesselaar M E, Romijn F P, Van Der Linden I K, Prins F A, Bertina R M, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.  J Thromb Haemost. 2007;  5 520-527
  CrossrefPubMedGoogle Scholar
• 67 Zwicker J I, Furie B C, Furie B. Cancer-associated thrombosis.  Crit Rev Oncol Hematol. 2007;  62 126-136
  Google Scholar
• 68 Furie B, Furie B C. Cancer-associated thrombosis.  Blood Cells Mol Dis. 2006;  36 177-181
  CrossrefPubMedGoogle Scholar
• 69 Zwaal R F, Comfurius P, Bevers E M. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids.  Biochim Biophys Acta. 2004;  1636 119-128
  CrossrefPubMedGoogle Scholar
• 70 Solum N O. Procoagulant expression in platelets and defects leading to clinical disorders.  Arterioscler Thromb Vasc Biol. 1999;  19 2841-2846
  PubMedGoogle Scholar
• 71 Faure V, Dou L, Sabatier F et al.. Elevation of circulating endothelial microparticles in patients with chronic renal failure.  J Thromb Haemost. 2006;  4 566-573
  CrossrefPubMedGoogle Scholar
• 72 Ogata N, Nomura S, Shouzu A, Imaizumi M, Arichi M, Matsumura M. Elevation of monocyte-derived microparticles in patients with diabetic retinopathy.  Diabetes Res Clin Pract. 2006;  73 241-248
  CrossrefPubMedGoogle Scholar
• 73 Ogata N, Imaizumi M, Nomura S et al.. Increased levels of platelet-derived microparticles in patients with diabetic retinopathy.  Diabetes Res Clin Pract. 2005;  68 193-201
  CrossrefPubMedGoogle Scholar
• 74 Omoto S, Nomura S, Shouzu A, Nishikawa M, Fukuhara S, Iwasaka T. Detection of monocyte-derived microparticles in patients with type II diabetes mellitus.  Diabetologia. 2002;  45 550-555
  CrossrefPubMedGoogle Scholar
• 75 Kline J A, Courtney D M, Kabrhel C et al.. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria.  J Thromb Haemost. 2008;  6 772-780
  CrossrefPubMedGoogle Scholar
• 76 Wolf S J, McCubbin T R, Nordenholz K E, Naviaux N W, Haukoos J S. Assessment of the pulmonary embolism rule-out criteria rule for evaluation of suspected pulmonary embolism in the emergency department.  Am J Emerg Med. 2008;  26 181-185
  CrossrefPubMedGoogle Scholar
• 77 Furie B, Furie B C. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation.  Trends Mol Med. 2004;  10 171-178
  CrossrefPubMedGoogle Scholar
• 78 Newman P JBM, Griffin J, Vague I J, Preissner K T. Minutes of Working Group in Vascular Biology. Available at: http://wwwmeduncedu/isth/ssc Accessed July 15, 2008
  Google Scholar
• 79 Enjeti A K, Lincz L F, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology.  Semin Thromb Hemost. 2007;  33 771-779
  Article in Thieme ConnectPubMedGoogle Scholar
• 80 Jy W, Hirstman L L, Jimenez J J. Measuring cell derived microparticles.  J Thromb Haemost. 2004;  2 1842-1851
  CrossrefPubMedGoogle Scholar
• 81 Freyssinet J M, Dignat-George F. More on: measuring circulating cell-derived microparticles.  J Thromb Haemost. 2005;  3 613-614
  CrossrefPubMedGoogle Scholar
• 82 Capitanio M, Normanno D, Pavone F S. High-precision measurements of light-induced torque on absorbing microspheres.  Opt Lett. 2004;  29 2231-2233
  CrossrefPubMedGoogle Scholar
• 83 Shapiro H M. Multiparameter flow cytometry of bacteria: implications for diagnostics and therapeutics.  Cytometry. 2001;  43 223-226
  PubMedGoogle Scholar
• 84 Shapiro H M. Multistation multiparameter flow cytometry: a critical review and rationale.  Cytometry. 1983;  3 227-243
  PubMedGoogle Scholar
• 85 Enjeti A K, Seldon M. Biomaleimide as a generic stain for detection and quantitation of microparticles.  Int J Lab Haematol. 2007 July;  , [Epub ahead of publication]
  PubMedGoogle Scholar
• 86 Exner T, Joseph J, Low J, Connor D, Ma D. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid.  Blood Coagul Fibrinolysis. 2003;  14 773-779
  CrossrefPubMedGoogle Scholar
• 87 Empson M B. Statistics in the pathology laboratory: diagnostic test interpretation.  Pathology. 2002;  34 365-369
  CrossrefPubMedGoogle Scholar
• 88 Empson M B. Statistics in the pathology laboratory: characteristics of diagnostic tests.  Pathology. 2001;  33 93-95
  CrossrefPubMedGoogle Scholar

Anoop K EnjetiM.B.B.S. M.D. F.R.C.P.A. 

Department of Haematology level 4, Hunter Haematology Research Group, New Medical Building, Calvary Mater Hospital

Waratah Newcastle 2298, Australia

Email: Anoop.Enjeti@mater.health.nsw.gov.au